{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:43:36Z","timestamp":1772297016880,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["QiSS program of the OPERA (Grant Number: JPMJOP1721)"],"award-info":[{"award-number":["QiSS program of the OPERA (Grant Number: JPMJOP1721)"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Astatine (<jats:sup>211<\/jats:sup>At) is a promising alpha emitter as an alternative to iodine (<jats:sup>131<\/jats:sup>I). We are preparing the first-in-human (FIH) clinical trial of targeted alpha therapy for differentiated thyroid cancer in consultation with Pharmaceuticals and Medical Devices Agency. Here, we performed an extended single-dose toxicity examination under a reliability standard, as a preclinical safety assessment of [<jats:sup>211<\/jats:sup>At]NaAt to determine the FIH dose.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>[<jats:sup>211<\/jats:sup>At]NaAt solution was injected into normal 6-week-old mice (male (<jats:italic>n<\/jats:italic>\u2009=\u200950) and female (<jats:italic>n<\/jats:italic>\u2009=\u200950), body weight: male 33.2\u2009\u00b1\u20091.7\u00a0g, female 27.3\u2009\u00b1\u20091.5\u00a0g), which were then divided into four groups: 5\u00a0MBq\/kg (<jats:italic>n<\/jats:italic>\u2009=\u200920), 20\u00a0MBq\/kg (<jats:italic>n<\/jats:italic>\u2009=\u200920), 50\u00a0MBq\/kg (<jats:italic>n<\/jats:italic>\u2009=\u200930), saline control (<jats:italic>n<\/jats:italic>\u2009=\u200930). The mice were followed up for 5\u00a0days (primary evaluation point for acute toxicity: <jats:italic>n<\/jats:italic>\u2009=\u200980) or 14\u00a0days (<jats:italic>n<\/jats:italic>\u2009=\u200920: evaluation point for recovery) to monitor general condition and body weight change. At the end of the observation period, necropsy, blood test, organ weight measurement, and histopathological examination were performed. For body weight, blood test, and organ weight, statistical analyses were performed to compare data between the control and injected groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No abnormal findings were observed in the general condition of mice. In the 50\u00a0MBq\/kg group, males (days 3 and 5) showed a significant decrease in body weight compared with the control. However, necropsy did not differ significantly beyond the range of spontaneous lesions. In the blood test, males (50\u00a0MBq\/kg) and females (50\u00a0MBq\/kg) showed a decrease in white blood cell and platelet counts on day 5, and recovery on day 14. In the testis, a considerable weight decrease was observed on day 14 (50\u00a0MBq\/kg), and multinucleated giant cells were observed in all mice, indicating a significant change related to the administration of [<jats:sup>211<\/jats:sup>At]NaAt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In the extended single-dose toxicity study of [<jats:sup>211<\/jats:sup>At]NaAt, administration of high doses resulted in weight loss, transient bone marrow suppression, and pathological changes in the testis, which require consideration in the FIH clinical trial.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12149-021-01612-9","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T15:04:38Z","timestamp":1618844678000},"page":"702-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Extended single-dose toxicity study of [211At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-2395","authenticated-orcid":false,"given":"Tadashi","family":"Watabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Kaneda-Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Ooe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Kurimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Murai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Shidahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Nishide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Shirakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"1612_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941\u20134.","journal-title":"J Nucl Med"},{"key":"1612_CR2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2967\/jnumed.118.222638","volume":"60","author":"T Watabe","year":"2019","unstructured":"Watabe T, Kaneda-Nakashima K, Liu Y, Shirakami Y, Ooe K, Toyoshima A, et al. Enhancement of 211At uptake via the sodium iodide symporter by the addition of ascorbic acid in targeted \u03b1-therapy of thyroid cancer. J Nucl Med. 2019;60:1301\u20137.","journal-title":"J Nucl Med"},{"key":"1612_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12149-018-1317-1","volume":"33","author":"M Hosono","year":"2019","unstructured":"Hosono M, Ikebuchi H, Nakamura Y, Yanagida S, Kinuya S. Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation. Ann Nucl Med. 2019;33:211\u201321.","journal-title":"Ann Nucl Med"},{"key":"1612_CR4","unstructured":"Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2). International Conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Jun 2009. https:\/\/www.pmda.go.jp\/files\/000156455.pdf"},{"key":"1612_CR5","doi-asserted-by":"publisher","first-page":"100757","DOI":"10.1016\/j.tranon.2020.100757","volume":"13","author":"Y Liu","year":"2020","unstructured":"Liu Y, Watabe T, Kaneda-Nakashima K, Ooe K, Shirakami Y, Toyoshima A, et al. Preclinical evaluation of radiation-induced toxicity in targeted alpha therapy using [211At] NaAt in mice: a revisit. Transl Oncol. 2020;13:100757.","journal-title":"Transl Oncol"},{"key":"1612_CR6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.tranon.2019.04.008","volume":"12","author":"H Sudo","year":"2019","unstructured":"Sudo H, Tsuji AB, Sugyo A, Nagatsu K, Minegishi K, Ishioka NS, et al. Preclinical evaluation of the acute radiotoxicity of the \u03b1-emitting molecular-targeted therapeutic agent 211At-MABG for the treatment of malignant pheochromocytoma in normal mice. Transl Oncol. 2019;12:879\u201388.","journal-title":"Transl Oncol"},{"key":"1612_CR7","unstructured":"Article 43, Standards of Reliability of Application Data, in Regulation for Enforcement of the Act on Securing Quality, Efficacy and Safety of products including pharmaceuticals and medical devices, order of the Ministry of Health, Labour and Welfare No. 1 of Feb 1, 1961."},{"key":"1612_CR8","unstructured":"ICH Harmonized tripartite guideline: Duration of chronic toxicity testing in animals (rodent and non rodent toxicity testing) S4. International Conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Sep 1998. https:\/\/www.pmda.go.jp\/files\/000156229.pdf"},{"key":"1612_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1177\/019262339802600611","volume":"26","author":"RC Johnson","year":"1998","unstructured":"Johnson RC, Dovey-Hartman BJ, Syed J, Leach MW, Frank DW, Sinha DP, et al. Vacuolation in renal tubular epithelium of Cd-1 mice: an incidental finding. Toxicol Pathol. 1998;26:789\u201392.","journal-title":"Toxicol Pathol"},{"key":"1612_CR10","first-page":"513","volume-title":"Pathology of the mouse. A reference and atlas","author":"A Nyska","year":"1999","unstructured":"Nyska A, Maronpot R. Adrenal gland. In: Maronpot R, editor. Pathology of the mouse. A reference and atlas. Saint Louis: Cache River Press; 1999. p. 513\u20134."},{"key":"1612_CR11","first-page":"134","volume-title":"Pathology of the mouse. A reference and atlas","author":"T Harada","year":"1999","unstructured":"Harada T, Enomoto A, Boorman GA, Maronpot R. Liver and gallbladder. In: Maronpot R, editor. Pathology of the mouse. A reference and atlas. Saint Louis: Cache River Press; 1999. p. 134\u20135."},{"key":"1612_CR12","unstructured":"ICH Harmonized tripartite guideline: Nonclinical evaluation for anticancer pharmaceuticals S9. International Conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Oct 2009. https:\/\/www.pmda.go.jp\/files\/000156321.pdf"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01612-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-021-01612-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01612-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T10:45:52Z","timestamp":1622803552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-021-01612-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1007\/s12149-021-01612-9","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"8 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}